{"id":"bl-b01d1","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL2110771","moleculeType":"Small molecule","molecularWeight":"311.45"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, BL-B01D1 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"BL-B01D1 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:26.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06618287","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-04","conditions":"Lung Cancer, Breast Cancer","enrollment":416},{"nctId":"NCT07106762","phase":"PHASE2, PHASE3","title":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-30","conditions":"Urothelial Cancer","enrollment":470},{"nctId":"NCT05983432","phase":"PHASE1","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","status":"RECRUITING","sponsor":"SystImmune Inc.","startDate":"2023-08-08","conditions":"Non Small Cell Lung Cancer, Lung Cancer, Breast Cancer","enrollment":470},{"nctId":"NCT07054567","phase":"PHASE2","title":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-21","conditions":"Cervical Cancer, Endometrial Cancer","enrollment":96},{"nctId":"NCT06475300","phase":"PHASE2","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-25","conditions":"Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor","enrollment":570},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06382116","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-22","conditions":"Non-small Cell Lung Cancer","enrollment":432},{"nctId":"NCT06304974","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":497},{"nctId":"NCT06382142","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-21","conditions":"Triple-Negative Breast Cancer","enrollment":418},{"nctId":"NCT06962787","phase":"PHASE2","title":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-07-28","conditions":"Renal Cancer","enrollment":260},{"nctId":"NCT06118333","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-12-04","conditions":"Nasopharyngeal Carcinoma","enrollment":386},{"nctId":"NCT06042894","phase":"PHASE2","title":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-12-12","conditions":"Breast Cancer","enrollment":58},{"nctId":"NCT05194982","phase":"PHASE1","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-11-29","conditions":"Locally Advanced or Metastatic Solid Tumor","enrollment":570},{"nctId":"NCT05990803","phase":"PHASE2","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-11-06","conditions":"Cervical Cancer","enrollment":130},{"nctId":"NCT06006169","phase":"PHASE2","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-10-20","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":186},{"nctId":"NCT05785039","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-04-20","conditions":"Urinary System Tumor, Solid Tumor","enrollment":76},{"nctId":"NCT05803018","phase":"PHASE1, PHASE2","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-06-25","conditions":"Gynecological Malignant Tumor, Solid Tumor","enrollment":38},{"nctId":"NCT05262491","phase":"PHASE1","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-02-14","conditions":"Gastrointestinal Tumor","enrollment":96},{"nctId":"NCT06008054","phase":"PHASE2","title":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-11-16","conditions":"Esophageal Cancer, Gastric Cancer, Colorectal Cancer","enrollment":376},{"nctId":"NCT05470348","phase":"PHASE1","title":"A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-08-11","conditions":"Breast Cancer, Solid Tumor","enrollment":36},{"nctId":"NCT05924841","phase":"PHASE2","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-11-10","conditions":"Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT05393427","phase":"PHASE1","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-02-15","conditions":"Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors","enrollment":4},{"nctId":"NCT05965856","phase":"PHASE2","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-12-11","conditions":"Urothelial Carcinoma, Solid Tumor","enrollment":52},{"nctId":"NCT05956587","phase":"PHASE2","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-01-29","conditions":"Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma","enrollment":121},{"nctId":"NCT06838273","phase":"PHASE3","title":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-02-24","conditions":"Non-small Cell Lung Cancer","enrollment":720},{"nctId":"NCT05880706","phase":"PHASE2","title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-07-19","conditions":"Non-small Cell Lung Cancer","enrollment":198},{"nctId":"NCT06857175","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-03-25","conditions":"Urothelial Carcinoma","enrollment":508},{"nctId":"NCT06986785","phase":"PHASE2","title":"A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-24","conditions":"Advanced Hepatocellular Carcinoma","enrollment":46},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT06951464","phase":"PHASE2","title":"A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2025-06-25","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06978114","phase":"PHASE2","title":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-06-10","conditions":"Advanced Biliary Tract Cancer","enrollment":46},{"nctId":"NCT06343948","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-04-24","conditions":"HR+HER2- Breast Cancer","enrollment":383},{"nctId":"NCT06471205","phase":"PHASE2","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-08-02","conditions":"Triple-negative Breast Cancer","enrollment":52},{"nctId":"NCT06437522","phase":"PHASE2","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT06498986","phase":"PHASE2","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06405425","phase":"PHASE2","title":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-29","conditions":"Urothelial Carcinoma","enrollment":52},{"nctId":"NCT06437509","phase":"PHASE2","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-06-13","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":66},{"nctId":"NCT06787664","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-01-16","conditions":"Chordoma","enrollment":40},{"nctId":"NCT06598787","phase":"PHASE2","title":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-10-17","conditions":"Recurrent Glioblastoma","enrollment":20},{"nctId":"NCT06500026","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-08-07","conditions":"Small Cell Lung Cancer","enrollment":714},{"nctId":"NCT06382129","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-05-17","conditions":"Non-small Cell Lung Cancer","enrollment":680}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iza-bren","izalontamab brengitecan","BMS-986507","No other name"],"phase":"phase_3","status":"active","brandName":"BL-B01D1","genericName":"BL-B01D1","companyName":"Sichuan Baili Pharmaceutical Co., Ltd.","companyId":"sichuan-baili-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BL-B01D1 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}